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CLINICAL INVESTIGATIONS 
Successful multiple segment coronary 
angioplasty: Effect of completeness of 
revascularization in single-vessel multilesions 
and multivessels 
A long-term follow-up study was performed to evaluate the long-term value of performing multiple 
dilatations according to their procedural (single-vessel multilesion or multivessel dilatations) and 
anatomic types (single-vessel disease wlth multiple dilatations or multivessel disease dilatations 
with complete and incomplete revascularlzation). From 1980 until 1988, 248 patients met the 
following criteria: (1) at least two lesions dilated (range: 2 to 4) and (2) all attempted lesions 
successfully dilated. The mean length of follow-up was 33 months. The end polnts analyzed were 
death, myocardial infarction, redilatation, and bypass surgery. No differences were found for 
these events between the single-vessel multilesion group (144 patients) and the multlvessel 
group (104 patients). The 4.5year probability of event-free survival was 88% and 70%, 
respectively, for the multilesion group and the multivessel group. In the event-free patients, 57% 
versus 59% were asymptomatic and 45% versus 48% were not taking antlanginal drugs. In the 
anatomic subgroups, there were less event-free patients in the cohort of Incompletely 
revascularized multivessel disease patients (55% of 55 patients) when compared with the cohort 
of those who were completely revascularized (84% of 79 patients) or when compared with the 
single-vessel disease multiple dilatation patients (74% of 107 patients). The 4.5-year event-free 
survival probability for each group was 44%, 78%, and 74%, respectively. This difference was 
caused by more infarctions (9% versus 2% versus 4%, respectively) and bypass operations in the 
multivessel disease, incomplete revascularization group (20% versus 5% versus lo%, 
respectively). In event-free patients, improvement of angina was similar and was documented in 
over 85% of patients in each group. Furthermore, the number of asymptomatic patients at 
follow-up was similar in all groups except that within the incomplete revascularizatlon group, less 
patients were free of antianginal drugs (21% versus 51% versus 48%). Finally, 48% of the entire 
cohort performed an exercise test 4.8 months (mean) after dilatation and no difference was 
found in any of the variables in any group. About 10% of the patients experienced angina and 
approximately 30% had a positive exercise test for ischemia by ST segment criteria. The 
functional performance in every group was over 90% of the predicted work load. These results 
suggest that completeness of revascularization in multivessel disease patients is an important 
prognostic variable. However, the symptomatic improvement after dilatation is very rewarding in 
all subsets of patients and argues in favor of the continued use of multiple dilatations as a 
treatment strategy. (AM HEART J 1990;120:1.) 
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balloon angioplasty of multiple segments is becoming 
increasingly frequent.3 The success rate and acute 
complication rate of such procedures have been 
4/l/20516 shown to be acceptable.4-6 However, the long-term 
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Fig. 1. Subgrouping methods. Two methods used: procedural and anatomic type. mud, Multivessel dis- 
ease; sud, single vessel disease; ues., vessel. 
Table I. Baseline characteristics of successfully dilated multiple segment patients, subgrouped by two different 
methods 
Subgroup method0 
Procedural type 
sod 
Anatomic type 
mud 
Characteristics S VML-PTCA MV-PTCA CR IR 
No. of patients 
Age (yr k SD) 
Sex (% male) 
Angina1 status (96 unstable) 
Hypertension (% ) 
Hyperlipemia (% ) 
Diabetes (% ) 
Smokers (% ) 
Old infarct (5%) 
Ejection fraction (Y’& < 0.50) 
Number of segments dilated (mean t SD) 
Number of vessels diseased 
144 
57.3 zk 9.4 
81 
34 
41 
25 
6 
50 
36 
13 
2.0 * 0.5 
I’olvd* 16 0 100 0 0 
“;>2vd* 22 75 0 96 56 
%3vd* 2 25 0 4 44 
104 
57.6 f  9.1 
83 
31 
43 
27 
0 
54 
55t 
14 
2.2 + 0.2 
107 79 55 
57.3 + 9.3 58.1 2 9.1 57.0 k 9.6 
81 78 a7 
35 29 34 
38 47 47 
29 24 20 
7 7 4 
52 53 47 
281 51 62 
10 14 15 
2.0 * 0.2 2.2 It 0.5 2.1 + 0.4 
CR, Complete revascularization in multivessel disease; IR, incomplete revascularization in multivessel disease; MV, multivessel; mvd, multivessel disease; 
svd, single-vessel disease; SVML, single-vessel multilesion; PTCA, percutaneous transluminal coronary angioplasty. 
BThe groups SVML-MV are the same patients as svd-CR-IR; they differ by seven patients hecause of nonavailable information on the diagnostic catheter- 
ization. 
*p < 0.0001 between SVML and MV and between CR and IR; ‘rp = 0.01 between SVML and MV; lp = 0.003 between svd and CR and p < 0.0001 between 
svd and IR. 
effect of the procedure is less well known, in part be- 
cause of the heterogeneity of the study populations, 
which differed with respect to distinct anatomic and 
procedural characteristics. 
The purpose of this study was to examine the 
long-term follow-up results of patients who under- 
went successful multiple segment angioplasty, ac- 
cording to the completeness of the revascularization 
and with respect to the different types of procedures 
(Fig. 1). Thus we specifically analyzed multivessel 
disease patients, separating them on the basis of 
completeness of revascularization, and then com- 
pared them with patients who had single-vessel dis- 
ease yet who had had multiple lesions dilated. We 
also examined the effect of performing single-vessel 
multilesion or multivessel dilatations on the clinical 
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Fig. 2. Sites of dilatation. LAD, Left anterior descending; LCX, left circumflex; MV, multivessel; RCA, 
right coronary; SVML, single-vessel multilesion. Left main and diagonals considered as LAD; obtuse mar- 
ginals considered as LCX. MV group may have more than one lesion dilated by artery. 
outcome. Finally, our results were compared with the 
results reported in the literature. 
METHODS 
Study patients. During the period from September 1980 
until January 1988, balloon angioplasty was performed in 
a total of 2098 consecutive patients at the Thoraxcenter in 
Rotterdam. Of these, 248 met the following criteria and 
made up the study group: (1) at least two lesions dilated in 
the same procedure (range: 2 to 4) and (2) all attempted le- 
sions successfully dilated. Reasons for exclusion included 
emergency angioplasty for acute myocardial infarction, 
patients with previous angioplasty, and patients with pre- 
vious coronary artery bypass surgery. 
Patients were classified according to the type of proce- 
dure (Fig. 1). Of the study group, 144 patients (58%) had 
single-vessel multilesion angioplasty, defined as at least 
two segments dilated in a single vessel even in the presence 
of multivessel disease; and 104 patients (42 % ) had multi- 
vessel angioplasty, defined as more than one vessel or ma- 
jor branches dilated in one or more segments. Patients were 
further separated on the basis of anatomic type (Fig. l), 
namely, single-vessel disease, IO7 patients (44 % ), or mul- 
tivessel disease 134 patients (56%). Dilatations of the 
single-vessel disease patients encompassed lesions dilated 
in the main vessel and/or its major branches. The multi- 
vessel disease patients were grouped, following dilata- 
tion, according to their revascularization status. Incom- 
plete revascularization, 55 patients (41% ), was defined as 
persistence of at least one undilated stenosis >50% in at 
least one vessel; complete revascularization, 79 patients 
(59%), was defined as absence of any remaining >50% 
stenosis. The single-vessel disease patients were not 
grouped in this way because they were all completely 
revascularized. Due to the retrospective nature of this 
study, seven patients (3% of the total group) could not be 
categorized in this manner because the diagnostic angio- 
grams were performed in another hospital and were un- 
available for analysis. 
The baseline characteristics of the subgroups are indi- 
cated in Table I. Unstable angina was defined as crescendo 
angina, de novo angina, or angina at rest. Prior infarction 
was defined according to the Minnesota c0de.l Ejection 
fraction was calculated from the contrast ventriculogra- 
phy, as previously described.8 There were significantly 
more previous infarctions in the multivessel group (57 pa- 
tients; 55% ) than in the single-vessel multilesion group (52 
patients; 36 % ). There were also significantly more previous 
infarcts in the complete and incomplete revascularization 
group compared with the single-vessel disease group: 40 
(51% ), 34 (62 % ), and 30 (28% ), respectively. The number 
of vessels diseased in the subgroups was also significantly 
different, as would be expected from the study design. No 
other significant differences existed between the groups. 
The vessel dilated, for the single-vessel multilesion group, 
and the combination of vessels, for the multivessel group, 
are indicated in Fig. 2. Left main and diagonal arteries 
were considered as left anterior descending artery, and 
obtuse marginals were considered as left circumflex 
artery. 
Coronary angiography. Coronary angiograms were ob- 
tained in multiple views and included hemiaxial angula- 
tions. The angiograms were interpreted by at least two ex- 
perienced angiographers. A significant stenosis was defined 
as a luminal narrowing of more than 50 % . 
Coronary angioplasty. The procedure used in our lab- 
oratory has been previously described.‘O Before the proce- 
dure, 250 mg of acetylsalicylic acid and 100 mg of heparin 
were administered intravenously. To prevent coronary 
spasm, intracoronary isosorbide dinitrate was given. All 
procedures were performed with a surgeon on standby. The 
method of angioplasty changed during the study period. 
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Table II. Follow-up events 
Subgroup method 
Euent 
Procedural type 
SVML-PTCA M V-PTCA 
Anatomic type 
mud 
CR IR 
Total no. patients 
Patients with F-UP 
Years of F-UP *SD 
Death (no. of patients) 
Myocardial infarct (no. of patients) 
RePTCA (no. of patients) 
CABG (no. of patients) 
Event-free patients 
144 104 107 79 
137 101 102 77 
2.68 i 1.47 2.72 i 1.45 2.73 2 1.49 2.75 i 1.41 
5 (3°C’) 7 (7Cc) 3 (3”;‘) * 3 (4CC’) 
8 (6’~ ) 4 (4cc ) 4 (4’;r) 2 (2”‘;,) 
13 (9c; ) 4 (4Cr ) 10 (lo”;’ 1 3 (4%) 
17 (12°C) 8 (8O; ) 10 (107 1 4 (5%) 
94 (69’<> ) 78 (77°C) 75 (74°C )t 65 (84”;‘) 
55 
53 
2.55 * 1.49 
6 (ll’r ) 
5 (9 ri’ ) 1 
3 (6’~‘) 
10 (20%)~ 
29 (55T)ll 
CABG, Coronary artery bypass grafting; F-UP, follow-up: other abbreviations as in Table I. 
*Death status is known for the total group of patients: six were cardiac, five were noncardiac, and the cause is uncertain for one patient. 
*p = 0.06, tp < 0.025 between svd and IR. 
lp = 0.02, §p = 0.01, lip = 0.0002 between CR and IR. 
Table Ill. Clinical status at follow-up in event-free patients 
Subgroup method 
Variable 
Procedural type Anatomic type 
wd mud 
SVML-PTCA MV-PTCA CR IR 
No. of patients 
Improvement of angina since PTCA (no. of patients) 
Free of angina at F-UP (no. of patients) 
Free of antianginal drugs (no. of patients) 
94 78 75 65 29 
94 (100fr )* 68 (87°C’ ) 71 (95’c )t 56 (86’; ) 28 (96’c ) 
54 (57°C ) 46 (59°C ) 46 (61 “c ) 38 (58”; ) 14 (48”; ) 
42 (45’~ ) 36 (46”, ) 36 (48”~ )$ 33 (51”U)§ 6 (21”c) 
Abbreviations as in Tables 1 and II. 
*p < 0.0005 between SVML and MV 
to. 1 > p > 0.5 between svd and CR. 
tp < 0.025 between svd and IR. 
$p < 0.01 between CR and IR. 
Before February 1983 a nonsteerable catheter system was 
used; from February 1983 through January 1986 a steerable 
system was used. Since then, the long guide wire technique 
or a monorail system has been in use. 
Angioplasty of the lesion considered to be the most im- 
portant (according to severity and morphology of the 
lesion, size of vessel, wall motion of area at risk, and local- 
ization of ischemic electrocardiographic changes at rest) 
was performed first. A stenosed vessel providing collater- 
als to another vessel was always dilated after the collater- 
alized vessel. Incomplete revascularization resulted from 
intentionally avoided lesions (chronic total occlusion, or an 
akinetic muscle region supplied by a stenotic vessel) and 
unattempted lesions because of an unsatisfactory result 
with the first attempted lesion. Also in unstable patients, 
it has been our policy to dilate only the culprit lesion. 
After the procedure, patients continued to receive treat- 
ment with nifedipine, 40 to 60 mg/day, and acetylsalicylic 
acid, 500 mg/day, for a period of 6 months. Procedural suc- 
cess was defined as reduction in the severity of the 
obstruction to less than 50% luminal diameter narrowing 
without major complications within 24 hours (myocardial 
infarct, emergency bypass surgery, or death). 
Follow-up. The following events were studied: death, 
myocardial infarction, redilatation, late coronary bypass 
surgery, presence of angina, improvement in angina1 status 
after dilatation, and use of antianginal medications (ni- 
trates, P-blockers, calcium channels blockers). This infor- 
mation was based on personal interviews, hospital data 
bases, questionnaires, or civil registries. Clinical follow-up 
data were obtained in 96.3% of the patients. The few re- 
maining patients were all living abroad and were unavail- 
able for follow-up. 
Exercise test. Patients performed a symptom-limited 
test on a bicycle ergometer with stepwise increments of 10 
W/min, as previously described.‘O The three orthogonal 
Volume 120 
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X,Y,Z leads of the Frank lead system were monitored. ST 
segment depression of at least 1 mm, 0.08 second after the 
J point was defined as an ischemic response. The maximal 
work load achieved was expressed as a percent of the nor- 
mal work load predicted for age, sex, and height. Complete 
information was obtained in 120 patients (48% of the total 
group). 
Statistics. BMDP software (Biomedical Data Package; 
University of California Press, Berkeley, Calif.) was used. 
Continuous variables were studied with Student’s t test 
while categorical variables were analyzed with the chi 
square or Fisher’s exact tests, whenever appropriate. Dif- 
ferences were considered significant at a probability value 
of < 0.05. The life-table analysis was done with the Kaplan- 
Meier method. The generalized Wilcoxon test was utilized 
to detect differences between subgroups. All statistical 
tests were two-tailed. 
RESULTS 
Clinical outcome at an average follow-up of 
2.70 + 1.46 years (range: .09 to 7.04 years) was com- 
pared for all subgroups. The length of follow-up was 
identical for all groups. 
Events (Tables II and III) 
Patients with single-vessel multilesion versus 
multivessel dilatation. Overall, there were no signif- 
icant differences in the following events: death, my- 
ocardial infarct, redilatation, and bypass surgery in 
the subgroups with single-vessel versus those with 
multi-vessel disease. In the patients without adverse 
events during the time elapsed since the angioplasty, 
there were significantly more patients with single- 
vessel multilesion dilatation who had an improve- 
ment in their anginal status (single-vessel multile- 
sion: 100% versus multivessel: 87 % ; p < 0.0005), al- 
though no differences were found either in the 
number of asymptomatic patients or in the number 
requiring antianginal drugs. 
Patients with multivessel disease, complete ver- 
sus incomplete revascularization. There was a highly 
significant difference in the total number of events 
between the complete versus the incomplete revas- 
cularization groups (complete revascularization: 16 % 
versus incomplete: 45% ; p = 0.0002). This was ex- 
plained by a greater number of bypass operations 
(complete revascularization: 5 % versus incomplete: 
20 % ; p = 0.01) and infarctions in the incomplete re- 
vascularization group (complete: 2% versus incom- 
plete: 9 % ; p = 0.02). Furthermore, incompletely re- 
vascularized and event-free patients more frequently 
required antianginal drugs (incomplete: 21% versus 
complete: 51% ; p < 0.01). Finally, there were no sig- 
nificant differences in the number of deaths, and the 
number of patients with redilatation, between the 
complete versus the incomplete revascularization 
groups. 
Patients with multivessel disease, incomplete re- 
vascularization versus patients with single-vessel 
disease. A significant difference was found between 
the multivessel, incomplete revascularization sub- 
group versus the subgroup with single-vessel disease 
in the total number of adverse events (incomplete: 
45 % versus single-vessel disease: 26 % ; p < 0.025). 
The patients with multivessel disease and incom- 
plete revascularization had a trend toward a greater 
number of deaths, infarctions, and bypass opera- 
tions. In the event-free patients, the requirement for 
antianginal drugs was significantly different between 
the single-vessel disease patients and the multivessel 
disease patients with incomplete revascularization 
(free of antianginal drugs; incomplete: 21% versus 
single-vessel disease: 48% ; p < 0.025). 
Patients with multivessel disease and complete 
revascularization versus patients with single-vessel 
disease. There were no significant differences be- 
tween the follow-up course of the group with multi- 
vessel disease and complete revascularization and the 
group with single-vessel disease. 
Exercise testing (Table IV). The exercise test was 
performed an average of 5.1 months (range = 0.1 to 
19.9 months) after the dilatation. There were no dif- 
ferences between the subgroups, and the functional 
performance was excellent for all patients. Few 
patients had angina (8% to 16%), but an ischemic 
response was demonstrated in one third of the 
patients. 
Life table analysis (Figs. 3 and 4). Since the number 
of patients who died was small, instead of a survival 
curve, the event-free survival (survival without redi- 
latation, bypass surgery, or infarction) was computed 
for both types of subgroup assignments. 
Patients with single-vessel multilesion versus 
multivessel dilatation. No differences were found 
between the patient group with single-vessel mul- 
tilesion dilatation compared with the group with 
multivessel dilatation. The 4.5-year probability of 
being alive and event-free was 68% (single-vessel) 
and 70% (multivessel). 
Patients with multivessel disease, complete ver- 
sus incomp2ete revascularization. There was a highly 
significant difference between the complete and in- 
complete revascularization groups in that the incom- 
pletely revascularized patients had a much shorter 
event-free survival (mean ? SE = 3.98 -+ 0.48 years 
for the incomplete revasculrirization group and 
5.08 & 0.23 years for the complete revascularization 
group, p = 0.0001) (Fig. 3). The 4.5year event-free 
survival probability was 78 % and 44 % , respectively, 
for both groups. 
Patients with multivessel disease and incomplete 
revascularization versus patients with single-vessel 
6 Samson et al. 
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Fig. 3. Event-free survival for both procedural types of dilatation (multilesion and multivessel dilata- 
tions). PTCA, Percutaneous transluminal coronary angioplasty. No significant difference found between 
both groups. 
Table IV. Results of exercise testing after PTCA 
Subgroup method 
Procedural type Anatomic type 
Parameter SVML MV 
svd 
CR 
mud 
IR 
No. of patients 73 47 52 33 34 
Time to test (months t SD) 4.27 + 4.16 4.89 + 3.50 4.47 * 4.38 4.98 k 3.36 4.08 k 3.74 
Work load (7, predicted k SD) 0.99 f 0.24 0.96 k 0.14 1.01 zk 0.24 0.99 -+ 0.15 0.93 k 0.18 
Double-product (HR . BP) + SD 24,459 + 9,291 26,762 f 8,548 24,987 + 9,036 26,631 * 9,030 24,662 -t 9,201 
Angina (no. of patients) 6 (9%) 6 (13%) 4(8%) 3 (9%) 5 (16%) 
ST depression (no. of patients) 15 (31%) 12 (44%) 15 (31%) 8(23%) 10 (31%) 
BP, Blood pressure; HR, heart rate; other abbreviations as in Tables I and II. 
p > 0.05 for all parameters. 
disease. There was also a significant difference 
between the group with multivessel disease and 
incomplete revascularization and the group with sin- 
gle-vessel disease in the mean event-free survival 
(incomplete: 3.98 k 0.48 years, single-vessel disease: 
4.89 + 0.27 years, p = 0.01). This trend was reversed 
in a 4.5-year probability of event-free survival of 44 % 
and 74%) respectively, for both groups. 
Patients with multivessel disease and complete 
revascularization versus patients with single-vessel 
disease. No differences were found between the 
group with multivessel disease and complete revas- 
cularization and the group with single-vessel disease. 
Other findings. Due to a difference in the extent of 
coronary artery disease between the complete and 
incomplete revascularization groups, an event-free 
survival curve was computed separately for the two- 
and the three-vessel disease patients. The mean + SE 
event-free survival was 5.51 +: 0.29 years for the 
two-vessel disease patients and was 3.53 f 0.54 years 
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Fig. 4. Event-free survival for the different anatomic types of dilatation. *p = 0.0001 between multives- 
se1 disease complete and incomplete revascularization; *p = 0.01 between single-vessel disease with mul- 
tiple dilatations and multivessel disease, incomplete revascularization. 
for the three-vessel disease patients (p = 0.01). Be- 
cause of this difference, the event-free survival anal- 
ysis was again performed for both complete and in- 
complete revascularization groups, but the three- 
vessel disease patients (n = 27 patients) were now 
excluded. This analysis again yielded a significant 
difference between patients in the complete and 
incomplete revascularization groups (complete: 
5.50 + 0.22 years versus incomplete: 4.04 f 0.68 
years; p = 0.001). For the completely revascularized 
patients, the 4.5 year-probability of event-free sur- 
vival was 81% , and this figure was 47 % at 3 years for 
incompletely revascularized patients. 
When we looked at different baseline characteris- 
tics (infarction, ejection fraction, unstable angina), 
there were no significant changes in the results of the 
life table analysis. Finally, it was also noticed that 
more than 50% of the events occurred in the first 7 
to 8 months of follow-up. 
DISCUSSION 
Multiple segment coronary angioplasty follow-up 
studies are notoriously different in terms of popula- 
tions involved, definitions used, and methods of 
reporting the results. They are thus difficult to inter- 
pret comprehensively. Outcome has often been re- 
ported as a total result without subgroup analysis 
(Table V). The effect of completeness of revascular- 
ization has also been reported, but some studies have 
not separated single-vessel disease patients and mul- 
tivessel disease patients, and some studies have also 
sometimes included single-vessel single lesion dila- 
tation in the comparisons (Table VI). Consequently, 
to obtain a clearer view of the long-term benefit of 
more than one dilatation done in the same procedure, 
we excluded single vessel single-lesion angioplasty 
and we report the results in terms of procedural type 
(multivessel versus single-vessel multilesion dilata- 
tions) in addition to anatomic type (single-vessel 
disease versus different revascularization status for 
multivessel disease). Last, to exclude the effect of the 
changing technology,g and since our interest was in 
the long-term effect of the procedure, our study con- 
sists of only successfully dilated cases. 
First, comparing patients succesfully dilated in one 
artery with those having more than one artery 
dilated, the only significant difference was the supe- 
rior improvement in angina1 status at follow-up in the 
event-free single-vessel multilesion population. How- 
ever, the fact that the number of asymptomatic 
patients and the number of patients not using an- 
tianginal drugs was the same, counterbalances this 
8 Samson et al. 
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Table V. Reported follow-up of multiple-lesion PTCA 
First No. of MV SVML Lesion by F-UP Death RePTCA CABG AMI 
author patients (?i) f%) patients fmo) oh) PZ) f%b) (0;) Symptoms 
DiSciascio’g 194 
Halon20 68 
DiSciascio21 50 
Lambert14 206 
Finci22 80 
Roubin23 298 
Dorros15 428 
Hartzlerla 500 
Cowley’6 100 
Myler24 494 
This study 248 
61.8 
65 
100 (3vDil) 
62 
100 
100 
84 
- 
86 
- 
42 
41.2 - 
35 2.4 
5 
38 2.2 
2.lv 
- - 
16 2.4 
2.7 
14 2.7 
- 2.3~ 
58 2.2 
>12 
30 
18.4 
>6 
12 
23 
28.3 
27 
26 
20.5 
33 
10 30 
0.9-1.0 IS-15 
99act - 
3.5 20.8 
5.6 21 
0 20 
1 20.8 
7-3 4-9 
- 37-27 $8 recurrence 
97 O, improvement 
4 4 34% recurrence 
1.8-3.8 1.8-2.6 70% _i class 1 
- 60f’o class 1 = 
88act 93act - 
5.8 - 68% no angina 
15 7.3 64Y improvement 
18 2.3 34 % recurrence 
- 83cc -5 class 1 
8-12 4-6 Improvement = 
875 -1oor,, * 
No angina = 
> 
t 
59“; -57rrm 
act, Actuarial survival: AMI, acute myocardial infarction; vDi1, vessel dilated; v, vessel; other abbreviations as in Tables I and II 
*Significant difference. 
tDual statement concerns MV versus SVML. 
difference. The diminished use of antianginal medi- 
cation is in agfeement with the results of a former 
study from our institution, which showed that there 
was a clear reduction in the use of these medications 
after angioplasty. l1 The absence of any significant 
difference in the single-vessel multilesion group com- 
pared with the multivessel group may seem surpris- 
ing at first glance, since 76% of the patients of the 
former group had only single-vessel disease and they 
also had fewer previous infarctions. However, the fact 
that these patients had a multisegment dilatation 
implies that they had at least one diffusely diseased 
coronary artery, which may in turn imply more severe 
disease in the other arteries, even if these were not 
significantly diseased by the usual criteria. Further- 
more, Roubin et a1.12 have found that the restenosis 
rate is associated with the number of segments 
dilated only in multilesion and not in multivessel di- 
latations. This may also help us to understand the 
absence of a difference between these two groups, 
since it is known that the clinical recurrence after di- 
latation is usually caused by restenosis.13p40 In addi- 
tion, restenosis probably explained the finding that 
the majority of events occurred in the first months 
after the procedure. l3 Only one other studyI has an- 
alyzed the influence of different types of procedures 
by making the differentiation in multivessel and sin- 
gle-vessel multilesion dilatations. Despite different 
definitions of their subgroups, Lambert et a1.14 re- 
ported identical follow-up results for these groups, 
and our results are similar to theirs. Compared with 
other long-term follow-up studies (Table V), our re- 
sults showed a lower event rate. This difference can 
probably be attributed, at least in those studies with 
a longer follow-up, 15, ~2 l8 to the increased severity of 
coronary disease of their patients, as is suggested by 
the greater number of lesions dilated. 
The second part of the study deals with the 
controversial topic of the influence of different de- 
grees of revascularization.5 While no differences were 
detected between the multivessel disease, complete 
revascularization group and the single-vessel disease 
group, the follow-up course of the multivessel dis- 
ease, incomplete revascularization group contrasted 
markedly with both. This held true even when con- 
sidering only the two-vessel disease patients in order 
to get a more homogeneous population. The discrep- 
ancy was particularly evident in the number of 
infarctions and bypass operations. The latter factor 
was probably in part due to the presence of totally 
occluded vessels, which led to a preference for bypass 
instead of dilatation. This was also noted in other 
studies (Table V). The difference between the groups 
becomes readily apparent in the first year after dila- 
tation, and it becomes more pronounced as time 
passes. This agrees with the findings of the recent re- 
port of Holmes et al. 25 Thus our data, which contain 
the longest follow-up compared with the rest of the 
literature, confirm the findings of several reports 
stating that the degree of revascularization is impor- 
tant in determining the evolution of multiple seg- 
ment dilatations,5* 27, 28, 35, 36 although others studies 
present contradictory results.26, 2g, 30, 32 In particular, 
the study of Holmes et al., 25 which contains a follow- 
up of 30 months’ duration on a very large number of 
patients (1183 patients) showed, as did our study, an 
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Table VI. Reported follow-up of revascularization status studies 
Complex PTCA 9 
No. Lesion F-UP DeathRePTCA CABG AMI 
First Patient of CR IR by (mo) CR-IR CR-IR CR-IR CR-IR 
author type patients (%I (W) patients (mean) (%) (%) CT@) (%I Symptoms Comments 
Holmes25 mvd 
svd 
Thomas26 mvd 
Deligonu16 mvd 
Deligonu127 mvd 
1183 61 39 - 
(Ilmvd) 
(89svd) 
92 20 
470 32 
229 34.5 
80 - 
68 2.2 
65.5 2.3 
Finci2s Mult 77 76 24 2.1 
Reederzg mvd 286 44 56 - 
Ilsley30 mvd 
De Feyter3’ Unst 
Wohlgel- Unst 
ernter32 
Hernan- mvd 
dez33 
200 
154 
27 
157 
Mata 2VPTC 74 
Mabin mvd 66 
Vandor- Mult 135 
maeP6 
This Mult 134 
study (all mvd) 
43 57 2.1 
72svd 28mvd 1 
0 
25 
100 1 16 
75 - 
85 
47 
46 
15 2.lv 
53 - 
54 2.4 
59 41 2.2 
30 
12.1 
27 
11 
24 
26.2 
11 
6 
10 
5.5 
10.5 
6 
33 
3-6 16-17 g-17* 3-7 20? -27 “<, More events 
recurrence with time 
and IR > CR 
o-o 11-12 5-l O-l 63 % -63% 26’c -21’0 
no angina no drugs 
5-5.5 13.5-13 6.7-15.6* 2.5-3.5 80’%-80% cl = 1 
(event-free) 
2.6-2.5 24-17.7 3.3:2.5 5.3-5.1 
(RePTCA > cl 3 
or CABG) 
5-28 - 81%24% 
no angina 
3.1-5* 19.7-8.8* 9.4-17* 7.1-9.4*30.9”0-32.5% But no 
angina difference 
in events 
if adjusted 
for baseline 
differences 
- 14-15 4-4 - 20$X-18% No difference 
recurrence in events 
167;,-29”;’ Good acute 
effect, more 
recurrence 
in IR 
17% 
recurrence 
o-1 5-13 5-11 8-l 66%-58% no No 
angina difference 
8 (event-free) 
- 2-10 44%-2000 
no angina 
o-o 6-6 13-23 - 80 5% -57 ‘?, IR = worse 
no angina F-UP 
o-3 3-16* 3-16* 3-o 90% less 91 “a -65 C;, *
angina are event-free; 
(both good effect 
groups) but more 
events 
4-11 4-6 5-19’ 2-9* 58 ?i, -48 0; IR = worse 
no angina, event-free 
51% -21 Ih survival 
no drugs* 
Mult, Multilesion PTCA; cl, New York Heart Association functional class: Unst, unstable; 2VPTC. two-vessel PTCA; other abbreviations as in Tables I, 
II, and V. 
*Statistically significant, differences; all the others are unstated or nonsignificant. 
event-free survival probability difference increasing also reported a significant difference in events be- 
with time of 62 % versus 37 % at 5 years, respectively, tween both revascularization groups at 27 months, 
for complete revascularization and incomplete revas- the incompletely revascularized patients having the 
cularization patients. However, these investigators worse prognosis. Curiously, as opposed to our find- 
included in their study 40% of single-vessel disease ings and the findings of others,35, 36 they did not see 
patients who had an 89 % complete revascularization any difference in the follow-up between the two- and 
rate. This obviously improves the outcome of their three-vessel disease groups. On the other hand, 
complete revascularization group. Deligonul et a1.27 Reeder et a1.2g showed, after correction by logistic 
10 Samson et al. 
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Table VII. Reported exercise test evaluation in multiple PTCA, multivessel disease PTCA, or with revascularization 
status studies 
First Patient 
author type 
ST 
Duration Double Angina segment 
No. of F-UP CR-ZR Work load product CR-ZR CR-ZR 
patients (mo) (4 CR-ZR CR-ZR c-o”o) (70) Comments 
HalonzO Mult 30 2 18.1-15.2 9.6-7.9 29,000-23,000* 0.6-1.5* CR = less ischemia 
(64% mvd) (min) (METS) (max 
dep (mm)) 
Thomas37 mvd 145 <2 459-450 - 22,968-23,120 13-13 19-34* CR = less 
ischemia, 
but same 
capacity 
Finciz2 Mult 43 11 117 (W) 26,400 355’ positive 
(100% mvd) test 
Wohlgelernter40 mvd 70 0.5 - 6-6 - 
Vandormae136 Mult 57 <lO days 514-492 - - O-20 26-37 No p value 
(84% mvd) but said to 
be different 
De Feyter31 Unst 118 2.6 75%61% 144-138 7-16* 15.31* CR = svd 
(28% mvd) (>905! (max HR) IR = mvd 
predicted) same capacity 
Deligonulz7 All 229 <l 488 85 (% age- 168 (max BP) 7.5-14 lo-36* Increased 
(54% mvd) predicted F-UP events 
max HR) among mvd 
and IR = worse 
This study Mult 67 4.5 99%-93% 26,631-24,662 9-16 23-31 no statistical 
(100% mvd) difference 
max BP, Maximal blood pressure; max dep, maximal depression (mm); max HR = maximal heart rate; METS, metabolic equivalents; other abbreviations 
as in Tables I, II, and VI. 
*Statistically significant differences. 
regression of important baseline mismatches in the 
patients of the National Heart, Lung, and Blood In- 
stitute (NHLBI) registry of angioplasty, no differ- 
ence in mortality or in morbidity of the patients at 26 
months between those with complete and those with 
incomplete revascularization. 
Finally, when analyzing the clinical status of event- 
free patients, we found a uniformly excellent result 
(Table III). However, this was attained with a more 
frequent use of antianginal medication in the incom- 
plete revascularization group of patients. Overall, 
about 90% of patients improved and 50% were 
asymptomatic, which is in general agreement with 
the reported results in the literature (Table VI). Only 
Thomas et al.26 also reported on the use of medica- 
tion and, while they had a proportion of asympto- 
matic patients similar to ours, a larger proportion of 
their completely revascularized patients needed an- 
tianginal medication compared with our patients 
(Thomas: 75 % versus this study: 50% ). The exercise 
testing also reflected this good clinical result (Table 
IV). It showed an excellent functional result that was 
associated with very few angina1 symptoms (8% to 
16 % ). Ischemia was found in almost one third of the 
patients, but the difference between the incomplete 
and the complete revascularization groups did not 
attain the significance level (23% and 31% ; p = NS). 
In this respect, our data differ from the findings in the 
literature on the subject (Table VII). In interpreting 
the exercise data, one must realize the likely possi- 
bility of a selection biais, since probably more pa- 
tients with recurrence of symptoms performed the 
test. 
In conclusion, we have shown that the effect on late 
clinical outcome of the performance of more than one 
dilatation in the same procedure is generally accept- 
able. In fact, there seems to be no difference in per- 
forming single-vessel multilesion or multivessel dila- 
tations. On the other hand, the completeness of 
revascularization in the multivessel subgroups is an 
important prognostic variable. The incompletely re- 
vascularized patients definitely fare less well with 
respect to follow-up events, especially when the ne- 
cessity of coronary bypass is considered. However, it 
is aIs0 apparent that even for these patients the ef- 
fect on their symptomatic status is very rewarding. 
Since all approaches to the treatment of coronary ar- 
tery disease are condemned to be palliative, we 
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believe that multiple dilatations, regardless of the 
degree of revascularization achieved in the multives- 
se1 disease subset, are an acceptable therapeutic op- 
tion if a careful selection of the patients is made to 
minimize acute complications. 
We thank Ron van Domburg of the Computer Group of the 
Thoraxcenter for his great help in data processing. 
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Defective coronary prostaglandin modulation in 
angina1 patients 
In order to investigate whether coronary vasodilating prostaglandins (PGI2 and PGE2) have a role 
in the pathophysiology of myocardial ischemia, 26 patients with angina pectoris and 23 control 
subjects (nonischemic patients) were studied by assessing coronary hemodynamics and 
prostaglandin formation in relation to sympathetic stimulation. Following a cold pressor test 
(CPT), coronary prostaglandin output markedly increased (p < 0.001) and coronary vascular 
resistance (CVR) decreased (p < 0.001) in all control subjects. In contrast, in angina1 patients 
prostaglandins in the coronary sinus were undetectable and after CPT prostaglandin output did 
not increase, whereas CVR paradoxically increased (p < 0.001). In control subjects the inhibition 
of coronary prostaglandin formation (by ketoprofen (1 mg/kg intravenously] or by aspirin [15 
mg/kg intravenously]) caused a paradoxical increase of CVR following CPT (p < 0.001). In angina1 
patients the inhibition of prostaglandins further exaggerated the increase of CVR after CPT 
(p < 0.001). These results indicate that coronary vasodilating prostaglandins PGlp and PGEp play 
a role in modulating coronary vascular response to sympathetic stimulation induced by CPT. Their 
defective production in angina1 patients may be responsible for the paradoxical increase in CVR 
following sympathetic stimulation. (AM HEART J 1990; 120:12.) 
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Florence and Rome, Italy 
Much evidence exists that the coronary vasculature 
of various animal speciesle3 and human cardiocoro- 
nary tissues4 are able to synthesize prostaglandins. In 
experimental preparations prostaglandin biosynthe- 
sis was induced by different stimuli, such as hypoxia 
From Clinica Medica I, University of Florence; and BDepartment of Cardi- 
ology, University La Sapienza, Rome. 
This work was supported in part by grant 87.00.38256 from the Consiglio 
Nazionale delle Ricerche, Rome, Italy. 
Received for publication Jan. 17, 1990; accepted Feb. 26, 1990. 
Reprint requests: Prof. G. G. Neri Serneri, Clinica Medica I, Viale Morgagni 
85, 50134 Florence, Italy. 
4/l/20448 
and angiotensin 11,5-7 and the formed prostaglandins 
have been shown to influence coronary vascular tone 
and coronary vascular resistance.lm3 In man, a rele- 
vant formation of cardiac and coronary prostaglan- 
dins was found following sympathetic stimulation 
induced by the cold pressor test (CPT).8 In this con- 
dition, vasodilating prostaglandins, i.e., prostacyclin 
(PGIz) and prostaglandin E2 (PGEz), were the main 
prostaglandins formed.8 Differing from the results in 
control subjects, in angina1 patients only negligible 
amounts or no PGI2 or PGEz have been found.g Since 
in a previous investigationlO cardiac and coronary 
prostaglandins have been shown to modulate the 
12 
